Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Blood Cancer Journal, Published online: 04 September 2020; doi:10.1038/s41408-020-00357-4Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

http://feeds.nature.com/~r/bcj/rss/current/~3/k7EUcgK1HEc/s41408-020-00357-4

Source: Blood Cancer Journal - September 3, 2020 Category: Hematology Authors: Meletios A. Dimopoulos Sagar Lonial Darrell White Philippe Moreau Katja Weisel Jesus San-Miguel Ofer Shpilberg Sebastian Grosicki Ivan Špička Adam Walter-Croneck Hila Magen Maria-Victoria Mateos Andrew Belch Donna Reece Meral Beksac Andrew Spencer Heath Source Type: research